Preoperative medical treatment in patients undergoing diabetic foot surgery with a Wagner Grade-3 or higher ulcer: a retrospective analysis of 52 patients

Murat Korkmaz, MD1*, Yalçın Erdoğan, MD2, Mehmet Balçi, MD3, Dilsad Amanvermez Şenarslan, MD4 and Neziha Yılmaz, MD3

1Department of Orthopaedics and Traumatology, Bozok University Medical Faculty, Yozgat, Turkey; 2Department of Family Medicine, Bozok University Medical Faculty, Yozgat, Turkey; 3Department of Infectious Diseases and Microbiology, Bozok University Medical Faculty, Yozgat, Turkey; 4Department of Cardiovascular Surgery, Bozok University Medical Faculty, Yozgat, Turkey

Diabetic foot ulcers (DFU) are one of the most important complications in people with diabetes mellitus. The present study was aimed to retrospectively review the efficacy of at least 1-week medical treatment before any surgical intervention in patients with Grade-3 and higher DFU according to Wagner’s classification. A total of 52 patients (36 males and 16 females) hospitalized and treated between June 2006 and February 2009 and had initially received therapeutic treatment (local wound care, antibiotic therapy and blood glucose regulation) for a period of at least 1 week were included in the study. The level of amputation, rates of ulcer recurrence and mortality in both groups were recorded in the following period of 2 years. Group 1 (did not respond to preoperative medical intervention) included 16 patients where a surgical debridement, flap or skin graft surgery was performed in 2 (12.5%) patients, major amputation was performed in another 2 (12.5%) patients and minor amputation was performed in the remaining 12 (75%) patients. Of 36 patients in Group 2 (did respond to preoperative medical intervention), 5 (13.9%) patients underwent the surgical debridement, flap or skin graft surgery, 8 (22.2%) patients had a major amputation and the remaining 23 (63.9%) patients lead to a minor amputation. The ulcer recurrence and mortality rates were obtained as 2 (12.5%) and 2 (12.5%) in Group 1 and 2 (5.6%) and 1 (2.8%) in Group 2, respectively. Despite the lower rates of ulcer recurrence and mortality in patients having adequate responses to initial treatment before surgical procedures were performed, no statistically significant difference was observed between the 2 groups. In addition, there was no statistically significant difference between the levels of amputation in both groups.

Keywords: diabetes mellitus; diabetic foot; amputation; medical treatment; mortality

Received: 23 May 2012; Revised: 9 July 2012; Accepted: 15 July 2012; Published: 17 August 2012
the Wagner classification (Table 1) (10). The amputation levels, reulceration and mortality rates within 24 months of the treatment were compared between the responding and non-responding patients to initial 1 week of therapeutic treatment.

Patients and methods
A total of 52 patients with Wagner Grade-3 and higher DFU hospitalized and treated between June 2006 and February 2009 were included in the study. A preoperative treatment of local wound care, antibiotic therapy and blood glucose regulation was initially given to all patients for a period of at least 1 week. Exclusion criteria for the study included patients with amputation performed for other reasons such as trauma or tumor, associated with entrapment neuropathies or vascular disease. The clinical follow-up periods and the results of the patients were retrospectively assessed.

The local wound care consisted of a saline wet-to-dry dressing applied to all patients for at least once a day for 1 week, and, if necessary, wound debridement was also performed. In the patients with malodorous and infected wounds, their feet were kept in a mixture solution of 100-mL Betadine® (each 1 mL contains 100-mg povidone-iodine, equivalent to 10-mg available iodine) and 1,000-mL saline for 5 min. Immediately after this procedure, saline wet-to-dry dressings were applied to their respective wounds.

Intravenous antibiotic therapy of ampicillin sulbactam has been shown to be safe and effective in the treatment of diabetic foot infections (11) and our hospitalized patients received the empirical therapy of ampicillin sulbactam, 4 g per day for at least 7 days prior to undergoing any type of diabetic foot surgery.

The mean fasting blood glucose level of the total of 52 patients with a long history of DM (14.9 years ±5.1) was 309 mg/dL during hospitalization. Long-lasting hypoglycemic treatments for all patients were stopped, and intensive insulin treatment (subcutaneous injections of regular human insulin for three times a day and insulin glargine for a single dose) was started via the calculation of total insulin dose with the formula of 0.5 IU/kg. After at least 7 days, the mean fasting blood glucose level of all patients was reported at 183 mg/dL.

Blood glucose levels less than 200 mg/dL, leukocyte counts in the reference ranges and C-reactive protein less than 10 mg/L were accepted as the criteria for adequate responses to 1 week of the preoperative medical intervention. Decrease in wound size and drainage, non-progressive necrosis and onset of granulation tissue were considered as clinical improvement of the preexisting DFU.

Patients were divided into two groups according to the responses of 1-week medical and local wound care treatment. Group 1 consisted of the patients without clinical improvement and who did not respond well to medical treatment. The patients having adequate responses to 1-week medical treatment were included into Group 2. The patients were followed for a mean period of 2.4 ± 0.5 years. The demographic and clinical data of the patients, levels of amputation, reulceration and mortality rates were retrospectively reviewed.

Statistical Package for the Social Sciences (SPSS) 15.0 was used for statistical analysis, and the variables were compared by using Chi-square and Mann–Whitney U tests. Values less than 0.05 were considered as significant.

Results
Demographic and clinical data of all patients are shown in Table 2. No adequate responses to the pre-operative 1-week medical intervention were obtained in 16 (30.8%) patients (Group 1). Of total 52 patients, 36 (69.2%) patients had been medically treated with adequate responses (Group 2). The healing rate without amputation in Group 1 was 12.5%, whereas in Group 2, complete wound healing was achieved in 5 of 36 feet (13.9%). These wounds were completely healed by surgical debridement, flap or skin graft surgery.

Out of 16 patients in Group 1, 2 patients (12.5%) had major amputations. One patient was amputated above the knee and 1 patient required a Syme’s amputation. In Group 1, 12 patients received minor amputations; where 1 patient (6.2%) had a transmetatarsal, 4 (25%) patients had a ray and 7 (43.8%) patients had toe amputations (Table 3). In Group 2, major amputations were performed in 8 patients (22.2%); 5 (13.9%) patients were amputated above the knee and 3 (8.3%) patients had a Syme’s amputation. Twenty-three (63.9%) patients had minor amputations; 12 (33.3%) patients had a transmetatarsal, 2 (5.6%) patients had a ray and 9 (25%) patients had toe amputations (Table 3).

There was no statistically significant difference between Groups 1 and 2 when comparing the minor and major amputation rates (p = 0.32, p = 0.09). The rates of ulcer recurrence and mortality were obtained as 2 (12.5%) and 2 (12.5%) in Groups 1 and 2 (5.6%) and 1 (2.8%) in Group 2, respectively. The comparison of both groups with respect to the ulcer recurrence and mortality

Table 1. Wagner’s classification for foot ulcers

| Grade | Description                                      |
|-------|-------------------------------------------------|
| 0     | Preulcerative lesion, healed ulcers, presence of osseous deformity |
| 1     | Superficial ulcer without subcutaneous tissue involvement |
| 2     | Penetration through the subcutaneous tissue (bone, tendon, ligament or joint capsule) |
| 3     | Osteitis, abscess or osteomyelitis              |
| 4     | Gangrene of the forefoot                        |
| 5     | Gangrene of the entire foot                     |
Etiologic factors of forefoot diabetic ulcers, Wagner’s classification, Osteomyelitis

| Mortality | Reulceration | Above the knee amputation | Syme amputation | Major amputation | Transmetatarsal Toe amputation | Minor amputation |
|-----------|-------------|---------------------------|-----------------|-----------------|-------------------------------|----------------|
| 2 (12.5)  | 1 (2.8)     | 1 (6.25)                  | 1 (6.25)        | 2 (12.5)        | 7 (43.8)                      | 12 (75)        |
| 1 (6.2)   | 2 (5.6)     | 3 (18.7)                  | 5 (13.9)        | 2 (12.5)        | 4 (25.0)                      | 5 (31.25)      |
| 1 (6.2)   | 2 (6.6)     | 5 (15.0)                  | 15.0 ± 5.2      | 5.0 ± 0.7       | 1.6 ± 0.7                     | 1.6 ± 0.7      |
| 10 (62.5) | 24 (66.7)   | 2 (12.5)                  | 14 (38.9)       | 14 (38.9)       | 14 (56.2)                     | 25 (75)        |
| 10 (62.5) | 14 (38.9)   | 11 (66.7)                 | 66.7 ± 9.8      | 10.6 ± 0.7      | 1.6 ± 0.7                     | 1.6 ± 0.7      |
| 14 (87.5) | 25 (69.4)   | 5 (31.25)                 | 14 (38.9)       | 2 (12.5)        | 8 (22.2)                      | 2 (12.5)       |

Table 2. Patients’ demographic and clinical data

| Group 1 (n = 16) | Group 2 (n = 36) |
|------------------|------------------|
| Female/male n (%) | 5 (31.2)/11 (68.8) | 11 (30.6)/25 (69.4) |
| Age, mean ± (year) | 66.7 ± 5.7 | 62.6 ± 10.6 |
| Duration of diabetes, mean ± (year) | 14.8 ± 4.9 | 15.0 ± 5.2 |
| Follow-up time, mean ± (year) | 1.6 ± 0.7 | 1.6 ± 0.0.3 |
| Peripheral neuropathy (+), n (%) | 9 (56.2) | 24 (66.7) |
| Peripheral vascular disease (+), n (%) | 10 (62.5) | 14 (38.9) |
| Osteomyelitis (+), n (%) | 14 (87.5) | 25 (69.4) |
| Etiologic factors of forefoot diabetic ulcers, n (%) | | |
| Unknown | 3 (18.7) | 10 (27.8) |
| Trauma | 4 (25) | 6 (16.7) |
| Shoe | 3 (18.7) | 5 (13.9) |
| Nail wound | 3 (18.7) | 5 (13.9) |
| Burns | 1 (6.25) | 6 (16.7) |
| Foot deformity | 2 (12.5) | 4 (11) |
| Wagner’s classification, n (%) | | |
| Grade 3 | 5 (31.25) | 14 (38.9) |
| Grade 4 | 9 (56.25) | 14 (38.9) |
| Grade 5 | 2 (12.5) | 8 (22.2) |

rates also showed no statistically significant difference (p = 0.06, p = 0.09). However, less ulcer recurrences and mortalities were clinically detected in Group 2.

Discussion

Long-term effects of DM on the microcirculation and on dermal collagen eventually result in skin disorders in almost all diabetic patients (4). These skin disorders cause a full-thickness penetration of the dermis of the foot, infection and ulceration in people with DM (12). Severity is classified using the Wagner’s classification system, which grades it from 1 to 5. Grade-3 ulcers are deep ulcers with cellulitis or abscess formation, often complicated with osteomyelitis. Ulcers with localized gangrene are classified as Grade 4, and those with extensive gangrene involving the entire foot are classified as Grade 5 (10). Grade 3 and higher DFU are usually serious infections requiring surgery. In this retrospective study, the rates of ulcer recurrence, mortality and amputation levels were not statistically different between Groups 1 and 2. One of our major limitations of the present study was the lack of glycosylated hemoglobin levels of the patients in both groups.

The relative risk of major amputation in people with DM compared with the population without DM is approximately 15 times higher (13–15). Targeting more-intensive glucose lowering modestly reduced major macrovascular events and increased major hypoglycemia over 4.4 years in persons with type 2 DM (16). Another study showed that good quality of life is significantly related to good diabetes self-management and fasting blood sugar control in type 2 diabetic patients with foot ulcers. Therefore, these patients should be encouraged to perform self-management for controlling their blood sugar and improving their quality of life (17). Imran et al. determined that the frequency of minor and major amputations increases with the higher grades of diabetic foot pathology. Poor glycemic control is a significant risk factor for amputation in diabetic patients (18). Together with early detection and treatment of foot lesions, normal blood glucose levels and early management of systemic complications such as nephropathy and arteriosclerosis are considered important to avoid major amputations (19–22). Most of the patients with Grade-3 and higher DFU usually undergo amputation or major surgery. The higher the level of amputation in the lower extremity, the greater the energy required for walking (23). In our study, there was no statistically significant difference between the rates of major amputations in both groups.

The reappearance of a foot lesion after the primary ulcer had healed is considered as an ulcer recurrence, and is mostly seen in patients with DM (24). The DFU recurrence can be prevented by instituting the multidisciplinary approach in the overall management of the diabetic patient. Additional preventive measures such as osseous and soft tissue reconstructions during the infection-free period together with education and routine follow-ups provide the basis for a long-term reduction of ulcer and infection recurrence with progressive deterioration of the prognosis (25). In the present study, the preoperative medical intervention was found to be effective clinically for reducing the ulcer recurrence rates, but this showed no statistical significance.

After a major amputation, patients with DM have an increased mortality rate compared with patients without

| Table 3. Amputation and complication rates |
|------------------------------------------|
| Group 1, n = 16 (%) | Group 2, n = 36 (%) |
|---------------------|---------------------|
| Healing without amputation | 2 (12.5) | 5 (13.9) |
| Minor amputation | 12 (75) | 23 (63.9) |
| Toe amputation | 7 (43.8) | 9 (25) |
| Transmetatarsal amputation | 1 (6.2) | 12 (33.3) |
| Ray amputation | 4 (25.0) | 2 (5.6) |
| Major amputation | 2 (12.5) | 8 (22.2) |
| Syme amputation | 1 (6.25) | 3 (8.3) |
| Above the knee amputation | 1 (6.25) | 5 (13.9) |
| Reulceration | 2 (12.5) | 2 (6.6) |
| Mortality | 2 (12.5) | 1 (2.8) |

Citation: Diabetic Foot & Ankle 2012, 3: 18838 - http://dx.doi.org/10.3402/dfa.v3i0.18838
DM (15). Lee et al. (27) concluded that, in patients with DM, the mortality rate among amputees was two times higher than in non-amputees, and that the 5-year survival rate after first amputation was 40.4% (26). In another study, there was an 8.7% mortality rate in patients with DM. In addition, it was also found that the mortality rate in major amputations was approximately three times higher than in minor amputations (28). In our study, the mortality rates between the two groups were not statistically different.

Conclusion
The reulceration and mortality rates were not statistically different between the two groups, but were found to be clinically lower in patients having an adequate response to preoperative medical intervention before undergoing any diabetic foot surgery.

Conflict of interest and funding
The authors have not received any funding or benefits from industry to conduct this study.

References
1. Delahoussaye-Shields RM, Delahoussaye-Soine RL, Soine EJ, Lopez FA. A 57-year-old man with diabetes and a toe infection. J La State Med Soc 2011; 163: 230-2.
2. Reiber GE, Lipsky A, Gibbons GW. The burden of diabetic foot ulcers. Am J Surg 1998; 176: 5-10.
3. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diab Care 1990; 13: 513-21.
4. Ragunatha S, Anitha B, Inamadar AC, Palit A, Devaramani SS. Cutaneous disorders in 500 diabetic patients attending diabetic clinic. Indian J Dermatol 2011; 56: 160-4.
5. Krishnan S, Nash F, Baker N, Fowler D, Rayman G. Reduction in diabetic autopsies over 11 years in a defined U.K. population: benefits of multidisciplinary team work and continuous prospective audit. Diab Care 2008; 31: 99-101.
6. Reiber GE, Boyko EJ, Smith DG. Lower extremity foot ulcers and amputations in diabetes. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH, eds. Diabetes in America. Washington, DC: U.S Govt. Printing Office 1995; pp. 409-28.
7. Armstrong DG, Lipsky BA. Diabetic foot infections: stepwise medical and surgical management. Int Wound J 2004; 1: 123-32.
8. Jeffcoate WJ, Chipchase SY, Ince P, Game FL. Assessing the outcome of the management of diabetic foot ulcers using ulcer-related and person-related measures. Diab Care 2006; 29: 1784-7.
9. Winkley K, Stahl D, Chalder T, Edmonds M, Ismail K. Risk factors associated with adverse outcomes in a population-based prospective cohort study of people with their first diabetic foot ulcer. J Diab Complications 2007; 21: 341-9.
10. Wagner FW Jr. The dysvascular foot: a system for diagnosis and treatment. Foot Ankle 1981; 2: 64-122.
11. Akova M, Ozebe O, Gülli I, Unal S, Gür D, Akalin S, et al. Efficacy of sulfadiazine-ampicillin for the treatment of severe diabetic foot infections. J Chemother 1996; 8: 284-9.
12. Hunt DL. Diabetes: foot ulcers and amputations. ClinEvid (Online) 2011; 26: pii: 0602.
13. Most RS, Sinnock P. The epidemiology of lower extremity amputations in diabetic individuals. Diab Care 1983; 6: 87-91.
14. Johansson A, Larsson GU, Ramstrand N, Turkiewicz A, Wierłn AB, Atrosi I. Incidence of lower-limb amputation in the diabetic and nondiabetic general population: a 10-year population-based cohort study of initial unilateral and contralateral amputations and reamputations. Diab Care 2009; 32: 275-80.
15. Schofield CJ, Libby G, Brennan GM, MacAlpine RR, Morris AD, Leese GP. DARTS/MEMO Collaboration Mortality and hospitalization in patients after amputation: a comparison between patients with and without diabetes. Diab Care 2006; 29: 2252-6.
16. Turnbull FM, Abaira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-98.
17. Navieharren R. Diabetes self-management, fasting blood sugar and quality of life among type 2 diabetic patients with foot ulcers. J Med Assoc Thai 2012; 95: 156-62.
18. Imran S, Ali R, Mahboob G. Frequency of lower extremity amputation in diabetics with reference to glycemic control and Wagner’s grades. J Coll Physicians Surg Pak 2006; 16: 124-7.
19. Miyajima S, Shirai A, Yamamoto S, Oka N, Matsushita T. Risk factors for major limb amputations in diabetic foot gangrene patients. Diab Res Clin Pract 2005; 71: 272-9.
20. Humphrey AR, Dowse GK, Thoma K, Zimmet PZ. Diabetes and nontraumatic lower extremity amputations. Incidence, risk factors, and prevention—a 12-year follow-up study in Nauru. Diab Care 1996; 19: 710-4.
21. Jbour AS, Jarrah NS, Radaideh AM, Shegem NS, Bader IM, Batieha AM, et al. Prevalence and predictors of diabetic foot syndrome in type 2 diabetes mellitus in Jordan. Saudi Med J 2003; 24: 761-4.
22. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006; 49: 1761-9.
23. Larsson J, Akeberg M, Apleqvist J, Stenström A. Sustained reduction in major amputations in diabetic patients: 628 amputations in 461 patients in a defined population over a 20-year period. ActaOrthop 2008; 79: 665-738.
24. Faglia E, Clerici G, Cersosimo J, Gabrielli L, Losa S, Mantero M, et al. Long-term prognosis of diabetic patients with critical limb ischemia: a population-based cohort study. Diab Care 2009; 32: 822-7.
25. Mittelmeier T, Haar P. The infected diabetic foot. Unfallchirurg 2011; 114: 227-35 (German).
26. Lee JS, Lu M, Lee VS, Russell D, Bahr C, Lee ET. Lower-extremity amputation. Incidence, risk factors, and mortality in the Oklahoma Indian Diabetes Study. Diabetes 1993; 42: 876-82.
27. Bahebeck J, Sobgui E, Loi C, Fong N, Mbanya JC, Sosso M. Limb-threatening and life-threatening diabetic extremities: clinical outcomes and outcomes in 56 patients. J Foot Ankle Surg 2010; 49: 43-6.
28. Hambleton IR, Jonnalagadda R, Davis CR, Fraser HS, Chaturvedi N, Hennis AJ. All-cause mortality after diabetes-related amputation in Barbados: a prospective case-control study. Diab Care 2009; 32: 306-7.

*Murat Korkmaz
Bozok Üniversitesi Tip Fakültesi Eğitim ve Araştırma Hastanesi
Yozgat, Turkey
Email: doktormuratkorkmaz@hotmail.com